118 related articles for article (PubMed ID: 1333504)
1. [Effect of chemotherapy on the prognosis of ovarian cancer].
Sugawa T; Umesaki N; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1135-41. PubMed ID: 1333504
[TBL] [Abstract][Full Text] [Related]
2. The current therapeutic approaches to advanced ovarian cancer.
Nishimura H; Hamaguchi K; Miyahara K; Tazaki T; Tateno N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1691-6. PubMed ID: 2277209
[TBL] [Abstract][Full Text] [Related]
3. [Studies of prognostic factor and chemotherapeutic effect of epithelial ovarian cancer using Cox's proportional hazard model].
Umesaki N; Sugawa T; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2351-6. PubMed ID: 8259850
[TBL] [Abstract][Full Text] [Related]
4. [Significance of intermittent CDDP therapy for improving long-term prognosis in patients with advanced ovarian cancer].
Umesaki N; Yamamoto A; Nakano M; Matsumoto Y; Tsuda K; Kawabata M; Sugawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1623-30. PubMed ID: 1744459
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of epithelial ovarian carcinoma with cisplatin and adriamycin: analysis of factors influencing prognosis in advanced cases].
Kamura T; Tsukamoto N; Jo S; Imachi M; Kaku T; Matsukuma K; Matsuyama T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2954-9. PubMed ID: 3021066
[TBL] [Abstract][Full Text] [Related]
6. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
[TBL] [Abstract][Full Text] [Related]
7. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
[TBL] [Abstract][Full Text] [Related]
8. Clinical remission criteria for epithelial carcinoma of the ovary.
Morikawa Y; Kawai M; Kano T; Kikkawa F; Oguchi H; Nakashima N; Ishizuka T; Furuhashi Y; Hattori SE; Kuzuya K
Gynecol Oncol; 1993 Mar; 48(3):342-8. PubMed ID: 7681806
[TBL] [Abstract][Full Text] [Related]
9. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
Kobayashi H; Hayata T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian cancer].
Hirabayashi K
Gan To Kagaku Ryoho; 1994 Mar; 21(4):452-8. PubMed ID: 8129385
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
Ivanov S; Ivanov S; Khadzhiolov N
Akush Ginekol (Sofiia); 2004; 43(6):17-9. PubMed ID: 15669647
[TBL] [Abstract][Full Text] [Related]
12. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
[TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
Wada Y; Suzuki M; Shinagawa S; Saito Y; Nishiya I; Maki M; Yajima A; Hiroi M; Sato A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2589-94. PubMed ID: 2505683
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
Barlow JJ; Lele SB; Emrich LJ
Am J Obstet Gynecol; 1985 Jun; 152(3):310-4. PubMed ID: 2988337
[TBL] [Abstract][Full Text] [Related]
15. [Combined chemotherapy of ovarian cancer with special reference to carboquone].
Sugimori H; Kidera Y; Matsuyama T
Gan To Kagaku Ryoho; 1982 Jan; 9(1):66-71. PubMed ID: 6307172
[TBL] [Abstract][Full Text] [Related]
16. [Intratumor chemotherapy of patients with cancer of the ovaries].
Vinokurov VL; Mitrokhina MV
Vopr Onkol; 1983; 29(8):58-61. PubMed ID: 6310891
[TBL] [Abstract][Full Text] [Related]
17. [A group study on prognosis of ovarian cancer in Japan].
Sugawa T; Umesaki N; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jul; 44(7):827-32. PubMed ID: 1500804
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years.
Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K
Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157
[TBL] [Abstract][Full Text] [Related]
19. [Importance of clinically prognostic factors in the treatment of advanced ovarian carcinoma].
Albrecht M; Goepel E; Simon WE; Trams G
Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):482-7. PubMed ID: 2993094
[TBL] [Abstract][Full Text] [Related]
20. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]